Verastem, Inc. VSTM
Set alert
At close
Pre-market · Nov 2, 8:48 AM ET
- YTD
- +26.30%
- 1 year
- +3.17%
- Open
- 9.63
- Prev close
- 9.75
- Mkt cap
- 1.18B
- Vol
- 2.41M
- Avg vol
- 3.30M
- EPS
- -2.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.50
- High
- 9.92
- Forward P/E
- -7.99
- Beta
- 0.39
- Short ratio
- 3.77
- Inst. own
- 82.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 8.10
- 200-d avg
- 6.15
- 1y target
- 17.11
5D chart
Signals (93)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| RSI: Oversold | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:20 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:00 PM | 6 days ago |
News
1 hour ago businesswire.com
Verastem Oncology to Participate in Upcoming November Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its…
-
2 weeks ago benzinga.com
Mizuho Maintains Outperform on Verastem, Raises Price Target to $14
Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $13 to $14.
-
2 weeks ago benzinga.com
Jefferies Maintains Buy on Verastem, Raises Price Target to $13
Jefferies analyst Faisal Khurshid maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $11 to $13.
-
2 weeks ago benzinga.com
RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19
RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $14 to $19.
-
2 weeks ago benzinga.com
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
-
2 weeks ago benzinga.com
BTIG Maintains Buy on Verastem, Raises Price Target to $24
BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $24.
2 weeks ago benzinga.com
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.
2 weeks ago benzinga.com
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
-
2 weeks ago benzinga.com
Verastem Oncology Appoints Michael P. Bailey As President And CEO, Effective January 1, 2027
Mr. Bailey will also continue to serve on the Company’s Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and continue…
-
2 weeks ago benzinga.com
Verastem Oncology Announces Initial Data In First Multi-Tumor Update From Ongoing TARGET-D 101 Phase 1/2 Clinical Trial Evaluating VS-7375; Data Demonstrate Robust Clinical Activity With Favorable Safety And Tolerability Profile Across Multiple Dose Levels And Tumor Types
VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a…
3 weeks ago benzinga.com
Verastem Oncology Q2 2026 Earnings Call Transcript
Verastem Oncology (NASDAQ:VSTM) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
3 weeks ago benzinga.com
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
-
4 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
-
1 month ago benzinga.com
Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026
RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
-
1 month ago benzinga.com
Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program
Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with…
-
2 months ago benzinga.com
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13
Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $14 to $13.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.
-
2 months ago benzinga.com
Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate
Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.43) by 18.6 percent. This is a 44.44 percent increase over losses of $(0.63) per…
-
3 months ago benzinga.com
Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal Cancer
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been…
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market session. The company's market cap stands at $17.1 billion. As per the news, the Q2 earnings report came…
-
3 months ago benzinga.com
Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain Metastases
TARGET-D 202 (NCT07659782) is a global, open-label, Phase 2 registration-directed trial evaluating VS-7375 monotherapy at the recommended Phase 2 dose (RP2D) of 900 mg daily (QD) in patients with…
3 months ago benzinga.com
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14
RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $15 to $14.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
-
4 months ago benzinga.com
Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary data from the…
4 months ago benzinga.com
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
Verastem updated RAMP 205 data showed 86% six-month survival in metastatic pancreatic cancer and continued tumor shrinkage.
-
4 months ago benzinga.com
Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And Nab-Paclitaxel In First-Line Metastatic Pancreatic Cancer
90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis6-month overall survival rate was 86%; follow-up continues and survival data continue to matureVerastem Oncology…
-
4 months ago benzinga.com
Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been…
-
4 months ago benzinga.com
Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial
Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trialCompany to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET
-
5 months ago benzinga.com
Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation, Dose Expansion, And Combination Clinical Trial Ongoing With Early Data Updates Expected In The First Half Of 2026 And More Mature Data Expected In The Second Half Of 2026
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug…
-
5 months ago benzinga.com
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $14
Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $16 to $14.
-
5 months ago benzinga.com
BTIG Maintains Buy on Verastem, Lowers Price Target to $18
BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $19 to $18.
-
5 months ago benzinga.com
Verastem Q1 Adj. EPS $(0.43) Beats $(0.46) Estimate, Sales $18.671M Miss $21.579M Estimate
Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.46) by 6.52 percent. This is a 45.57 percent increase over losses of $(0.79) per…
-
6 months ago benzinga.com
Verastem Oncology Rolls Out Its Reimagine Recurrent Low-Grade Serous Ovarian Cancer Campaign For AVMAPKI FAKZYNJA CO-PACK
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
-
7 months ago benzinga.com
Verastem Oncology To Present Long-Term Phase 2 RAMP 201 Data On AVMAPKI FAKZYNJA In Recurrent Low-Grade Serous Ovarian Cancer At SGO 2026
Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trialVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical…
-
8 months ago benzinga.com
Verastem Q4 Adj. EPS $(0.48) Beats $(0.53) Estimate, Sales $17.535M Beat $15.682M Estimate
Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.26 percent. This is a 20 percent increase over losses of $(0.60) per…
-
9 months ago benzinga.com
HC Wainwright & Co. Assumes Verastem at Buy, Announces Price Target of $18
HC Wainwright & Co. analyst Andres Y. Maldonado assumes Verastem (NASDAQ:VSTM) with a Buy rating and announces Price Target of $18.
-
9 months ago benzinga.com
Verastem Oncology Expects $17.5M In Q4 2025 Revenues For AVMAPKI FAKZYNJA CO-PACK, Up From $12.5M In Q4 2024, While Advancing VS-7375 Development In 2026
Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million…
10 months ago benzinga.com
Verastem Ends Lung Cancer Trial, Reallocates Resources
The RAMP 203 trial in advanced KRAS G12C–mutated non-small cell lung cancer has been discontinued due to increased competition.
10 months ago benzinga.com
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
10 months ago benzinga.com
Verastem Oncology Announces Intent To Discontinue RAMP 203 Clinical Study In Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of…
-
10 months ago benzinga.com
Verastem Appoints John Johnson As Chairman Of The Board; Co. Announces That It Has Completed The Additional Patient Enrollment For Ramp 301, Its International Phase 3 Confirmatory Trial In Recurrent LGSOC
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to…
11 months ago benzinga.com
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session